rs-fMRI in CML patients with fatigue and cognitive impairment on TKIs
Research type
Research Study
Full title
Resting state functional magnetic resonance imaging in chronic myeloid leukaemia patients with fatigue and cognitive impairment on tyrosine kinase inhibitors
IRAS ID
250152
Contact name
Jane F Apperley
Contact email
Sponsor organisation
Imperial College London and Imperial College Healthcare NHS Trust
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Chronic myeloid leukaemia (CML) is one of the rare blood malignancies that have a targeted oral treatment, known as tyrosine kinase inhibitors (TKIs). Treating CML patients with these agents allows the achievement of excellent response rates, and hence CML patients enjoy a life expectancy comparable to the normal population. Some patients achieving and maintaining a very deep response can even stop their medication without losing their response. However most patients will remain on lifelong daily oral therapy so it is important to minimise side effects. Fatigue and cognitive impairment are very common side effects of these agents and have significant effect on the quality of life of the patients. The cause of these side effects is unknown and there are no simple remedies.
Resting state functional magnetic resonance imaging (rs-fMRI) is a relatively novel imaging modality that can map the activity of the different areas of the brain while the individual is at rest. We wish to look at two cohorts of patients by rs-fMRI to see if we can identify changes that might account for the cognitive impairment.
The first group are newly diagnosed patients who will be imaged at diagnosis and then after 6 months of TKI therapy. The second cohort is patients who have been on long-term TKI and who have achieved such deep and durable responses that they are being offered the chance to discontinue treatment; they will be imaged just before stopping therapy and 6 months later.REC name
North West - Preston Research Ethics Committee
REC reference
22/NW/0058
Date of REC Opinion
24 May 2022
REC opinion
Further Information Favourable Opinion